Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
16 Settembre 2024 - 1:00PM
Business Wire
The Arizona Bioindustry Association, Inc. (AZBio) and Castle
Biosciences, Inc. (Nasdaq: CSTL), a company improving health
through innovative tests that guide patient care, today announced
that Kristen Oelschlager, R.N., Castle’s chief operating officer,
has been named the 2024 Jon W. McGarity Arizona Bioscience Leader
of the Year. The award, presented by AZBio, recognizes Oelschlager
for her outstanding leadership that has contributed significantly
to the progression of the bioscience industry in Arizona.
“Kristen’s tenacity, thoughtful leadership and passion for
people have had an immeasurable influence on Castle’s growth
trajectory, our strong workplace culture and the legacy of improved
patient care that we are working to build as a company,” said Derek
Maetzold, president and chief executive officer of Castle. “It has
been an honor to work alongside her for the better part of two
decades, and I can think of no person more deserving of this
honor.”
“The entirety of Kristen’s professional career has been
dedicated to positively impacting the care of patients, first at
the bedside as a nurse and now more broadly through her work at
Castle Biosciences,” said Joan Koerber-Walker, president and chief
executive officer of AZBio. “Kristen’s contributions to the
advancement of patient care are helping to re-shape disease
management paradigms in Arizona and beyond, and we are pleased to
honor her as the 2024 Arizona Bioscience Leader of the Year.”
In 2008, Oelschlager joined Maetzold and Toby Juvenal, chief
commercial officer, in a new entrepreneurial endeavor as a founder
of Castle Biosciences, a company offering innovative testing
solutions to guide treatment decisions for patients impacted by
cancers. Her diverse background spanning more than 15 years in
clinical nursing, operations services and research has provided a
unique perspective that has been instrumental in the Company’s
ongoing growth and success.
Arizona’s life science community will gather on September 18,
2024, at the Phoenix Convention Center for the AZBio Awards where
Oelschlager will be presented with the award.
About The Arizona Bioindustry Association, Inc.
(AZBio)
For 20 years, the Arizona Bioindustry Association has supported
life science innovation and life science innovators in Arizona. A
key component in Arizona’s life science ecosystem, AZBio is the
only statewide organization exclusively focused on Arizona’s
bioscience and medical technology industry. AZBio membership
includes patient advocacy organizations, life science innovators,
educators, healthcare partners and leading business organizations.
AZBio and its members work to advance health innovation and to
ensure that the value delivered by our community’s life-changing
and lifesaving innovations benefits people in Arizona and around
the world. For more information on AZBio, visit www.AZBio.org.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
Barrett’s esophagus, mental health conditions and uveal melanoma.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to help guide systemic therapy
selection for patients with moderate-to-severe atopic dermatitis,
psoriasis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME
and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240916356187/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Grafico Azioni Castle Biosciences (NASDAQ:CSTL)
Storico
Da Feb 2025 a Mar 2025
Grafico Azioni Castle Biosciences (NASDAQ:CSTL)
Storico
Da Mar 2024 a Mar 2025